
Key Takeaways
- Hispanic patients receiving endocrine therapy had higher nonalcoholic fatty liver disease (NAFLD) cumulative incidence (20.6% vs 11.7%) and shorter NAFLD-free interval (HR, 2.23) than non-Hispanic patients.
- Multivariable predictors of NAFLD included Hispanic ethnicity (HR, 1.75) and elevated body mass index (25-29.9: HR, 2.91; ≥30: HR, 3.15), independent of endocrine therapy type or duration.
- Recurrence-free and overall survival did not significantly differ by Hispanic ethnicity despite NAFLD risk enrichment, indicating a survivorship toxicity signal rather than efficacy decrement.
- Among ≤45-year ER-positive/HER2-negative cases, 0 to 5 years post partum was associated with higher Oncotype Dx scores than nulliparity (β, 4.38), peaking at 1 year (β, 13.22).
- Elevated genomic risk signals persisted up to approximately 3 years post partum, supporting redefining postpartum breast cancer as 0 to 3 years post partum and broadening consideration of recurrence scoring in low-risk appearing postpartum presentations.
Hispanic ethnicity was found to be independently associated with a higher risk of nonalcoholic fatty liver disease (NAFLD) among patients with hormone receptor–positive early-stage breast cancer who received endocrine therapy (ET), according to findings from a retrospective study. Additionally, patients with postpartum breast cancer (PPBC) experienced a higher recurrence score in the first year post partum, with a trend toward increase up to 3 years post partum, supporting the refinement of what constitutes PPBC to be 0 to 3 years post partum, according to data from another retrospective study.
During the OncLive National Fellows Forum on breast cancer, which was held during the 2025 San Antonio Breast Cancer Symposium, oncology fellows with an interest in breast cancer from across the country gathered to share their research, network with their peers, and receive feedback from expert mentors. Vishnu Prasath, MD, and his group presented a study titled “Ethnic Differences in NAFLD Among Women With Early-Stage Breast Cancer Receiving Endocrine Therapy.” Lisa Zhang, MD, and her team presented a study titled “Clinical Implications of Genomic Signatures in Postpartum Breast Cancer (PPBC).”
How did ethnic differences affect the incidence of NAFLD in ET-treated early-stage breast cancer?
Prasath and his teammates conducted a single-center retrospective cohort study that aimed to assess ethnic difference in NAFLD onset in women with early-stage hormone receptor–positive breast cancer who received ET from 2010 to 2013 at Loma Linda University in California.1 The total cohort (n = 465) included 107 Hispanic and 358 non-Hispanic patients. The primary outcome was time to NAFLD onset; secondary end points included the cumulative incidence of NAFLD, recurrence-free survival (RFS), and overall survival (OS).
Read full article: https://www.onclive.com/view/experts-reveal-ethnic-differences-in-early-hr-breast-cancer-and-genomic-insights-in-women-postpartum







